Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | SI | P14410 | 2/20 | 0.61 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 4/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | POLA1 | P09884 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15688315 | 0.97 | MGAM (0.58) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL3585736 | 0.88 | MGAM (0.74) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL115815 | 0.88 | MGAM (0.50) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL11756126 | 0.87 | TSHR (0.61) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL18914895 | 0.86 | TSHR (0.48) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL11932196 | 0.86 | TSHR (0.48) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL11779901 | 0.86 | MGAM (0.48) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL10485430 | 0.86 | MGAM (0.48) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL17522586 | 0.86 | MGAM (0.70) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL10012431 | 0.86 | MGAM (0.48) | MGAMGAASIMGAM2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1856 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116917446-B | Hydroprocessing process using catalyst sequences with nickel, molybdenum and tungsten based catalysts | IFP Energies Nouvelles (FR) | 2026-05-26 | — | — | CN | claimed |
| US-12629669-B2 | Method for rejuvenating a catalyst from a hydroprocessing and/or hydrocracking process | IFP Energies Nouvelles (FR) | 2026-05-19 | — | — | US | claimed |
| EP-4558588-B1 | HYDROTREATMENT PROCESS USING A SEQUENCE OF CATALYSTS WITH A CATALYST BASED ON NICKEL AND TUNGSTEN ON A SILICA-ALUMINA SUPPORT | IFP ENERGIES NOW (FR) | 2026-05-13 | — | — | EP | claimed |
| WO-2026087561-A1 | RETARDING AGENT IN ISOCYANATE COMPONENT OF POLYURETHANE/UREA CEMENTITIOUS HYBRID SYSTEMS | SIKA TECHNOLOGY AG (CH) | 2026-04-30 | — | — | WO | claimed |
| EP-4733284-A1 | RETARDING AGENT IN ISOCYANATE COMPONENT OF POLYURETHANE/UREA CEMENTITIOUS HYBRID SYSTEMS | Sika Technology AG (CH) | 2026-04-29 | — | — | EP | claimed |
| US-12590254-B2 | Method for hydrodesulfurisation of a petroleum fraction using a catalyst containing a graphitic material characterised by the H/C ratio thereof | IFP Energies Nouvelles (FR) | 2026-03-31 | — | — | US | claimed |
| US-12521702-B2 | Trimetallic catalyst made from nickel, molybdenum and tungsten and use thereof in a hydrotreatment and/or hydrocracking process | IFP Energies Nouvelles (FR) | 2026-01-13 | — | — | US | claimed |
| EP-4251712-B1 | METHOD FOR HYDRODESULFURISATION OF A PETROLEUM FRACTION USING A CATALYST CONTAINING A GRAPHITIC MATERIAL CHARACTERISED BY THE H/C RATIO THEREOF | IFP ENERGIES NOW (FR) | 2026-01-07 | — | — | EP | claimed |
| US-12467003-B2 | Hydrotreating process using a sequence of catalyst with a catalyst based on nickel, molybdenum and tungsten | IFP Energies Nouvelles (FR) | 2025-11-11 | — | — | US | claimed |
| EP-4558588-A1 | HYDROTREATMENT PROCESS USING A SEQUENCE OF CATALYSTS WITH A CATALYST BASED ON NICKEL AND TUNGSTEN ON A SILICA-ALUMINA SUPPORT | IFP Energies nouvelles (FR) | 2025-05-28 | — | — | EP | claimed |
| EP-1403264-B1 | Process for the industrial synthesis of 5-amino-3-carboxymethyl-4-cyano-2-thiophenecarboxydimethylester | SERVIER LAB (FR) | 2004-12-29 | — | — | EP | claimed |
| CN-1500783-A | Process for industrial synthesis of substituted thiophenecarboxylates and use of the compounds | ɪά��ʵ���� | 2004-06-02 | — | — | CN | claimed |
| US-20040059135-A1 | Process for the industrial synthesis of the methyl diester of 5-amino-3-carboxymethyl-4-cyano-2-thiophenecarboxylic acid, and application to the synthesis of bivalent salts of ranelic acid and their hydrates | LES LABORATOIRES SERVIER (FR) | 2004-03-25 | — | — | US | claimed |
| EP-0739199-B1 | ESTRADIOL PENETRATION INTENSIFIER FOR TRANSDERMAL ADMINISTRATION | LOHMANN THERAPIE SYST LTS (DE) | 2002-04-03 | — | — | EP | claimed |
| US-6090404-A | SUSTAINED RELEASE PATCH | LTS LOHMANN THERAPIE-SYSTEME GMBH (DE) | 2000-07-18 | — | — | US | claimed |
| EP-0739199-A1 | ESTRADIOL PENETRATION INTENSIFIER FOR TRANSDERMAL ADMINISTRATION | LTS LOHMANN Therapie-Systeme GmbH (DE) | 1996-10-30 | — | — | EP | claimed |
| WO-1995019162-A1 | ESTRADIOL PENETRATION INTENSIFIER FOR TRANSDERMAL ADMINISTRATION | LTS LOHMANN THERAPIE-SYSTEME GMBH & CO. KG (DE) | 1995-07-20 | — | — | WO | claimed |
| EP-0108332-A1 | Preparation of acetone dicarboxylic acid diester | UBE INDUSTRIES, LTD. (JP) | 1984-05-16 | — | — | EP | claimed |
| US-4333878-A | MAKING 1,4-DIALKYLPYRROLE DIESTERS FROM 2-HYDROCARBOXY-1-NITROALKANE AND ENAMINE OF DIALKYL ACETONE DICARBOXYLATE | ETHYL CORPORATION (US) | 1982-06-08 | — | — | US | claimed |
| US-4150236-A | Steroidal intermediates from the condensation product of dimethyl-3-ketoglutarate and glyoxal | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH, EDUCATION AND WELFARE (US) | 1979-04-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040059135-A1 | Process for the industrial synthesis of the methyl diester of 5-amino-3-carboxymethyl-4-cyano-2-thiophenecarboxylic acid, and application to the synthesis of bivalent salts of ranelic acid and their hydrates | CA7, CA2, SLC38A7 | MGAM 1309/4885GAA 4098/4885SI 18/4885 |
| US-12590254-B2 | Method for hydrodesulfurisation of a petroleum fraction using a catalyst containing a graphitic material characterised by the H/C ratio thereof | HMOX2, SCO2, HAO2 | MGAM 1289/4885GAA 2928/4885SI 1368/4885 |
| US-12629669-B2 | Method for rejuvenating a catalyst from a hydroprocessing and/or hydrocracking process | HOGA1, GK, PCK2 | MGAM 1678/4885GAA 1733/4885SI 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.